ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,830Medicare Part D Prescriptions Filled, Including Refills

Rank: 75 out of 1269

$621K Total Retail Price of All Prescriptions

Rank: 81 out of 1269

272 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
96% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

21% of this provider’s 272 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

4% of this provider’s 272 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 7,675 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$63 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

36 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
AMLODIPINE BESYLATE 374 335 1 2
WARFARIN SODIUM 315 309 2 12
TRAMADOL HCL 304 263 3 16
FUROSEMIDE 265 242 4 5
METOPROLOL TARTRATE 261 206 5 6
LISINOPRIL 248 214 6 1
LANTUS 224 166 7 39
SIMVASTATIN 207 180 8 3
MIRTAZAPINE 190 173 9 24
LEVOTHYROXINE SODIUM 183 147 10 4
OMEPRAZOLE 177 146 11 8
LEVETIRACETAM 141 74 12 55
POLYETHYLENE GLYCOL 3350 139 65 13 50
GABAPENTIN 134 112 14 17
NAMENDA 110 110 15 38
METOCLOPRAMIDE HCL 107 62 16 155
LIDODERM 107 99 16 56
BACLOFEN 104 20 18 103
LOVASTATIN 104 89 18 30
SERTRALINE HCL 101 101 20 23
PANTOPRAZOLE SODIUM 101 83 20 18
TRANSDERM-SCOP 101 81 20 319
CLOPIDOGREL 97 92 23 32
IPRATROPIUM-ALBUTEROL 95 51 24 86
NOVOLOG 89 66 25 82
KLOR-CON M20 89 65 25 60
CITALOPRAM HBR 87 73 27 21
LACTULOSE 86 33 28 67
LEVOFLOXACIN 84 66 29 75
DONEPEZIL HCL 80 69 30 22
TRAZODONE HCL 80 52 30 36
RISPERIDONE 79 66 32 43
RANITIDINE HCL 78 47 33 27
OXYCODONE HCL 78 24 S2 33 34
HYDRALAZINE HCL 77 76 35 48
METFORMIN HCL 77 46 35 9
CYMBALTA 76 75 37 70
SULFAMETHOXAZOLE-TRIMETHOPRIM 75 61 38 84
PRAVASTATIN SODIUM 74 74 39 11
ESCITALOPRAM OXALATE 71 58 40 58
DILANTIN 69 59 41 184
SANTYL 68 53 42 101
QUETIAPINE FUMARATE 67 61 43 53
DIGOXIN 61 42 44 62
ATORVASTATIN CALCIUM 59 41 45 7
LABETALOL HCL 59 54 45 160
LYRICA 57 35 47 92
ALBUTEROL SULFATE 56 44 48 88
METOPROLOL SUCCINATE 56 44 48 13
NOVOLIN R 55 36 50 211
JANTOVEN 54 53 51 52
AMOX TR-POTASSIUM CLAVULANATE 53 42 52 110
POTASSIUM CHLORIDE 52 34 53 26
PLAVIX 51 48 54 47
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 6, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.